Details of the Drug-Related molecule(s) Expression Atlas

General Information of Drug (ID: DM8HO1L)

Drug Name
Pyridostigmine Drug Info
Synonyms
Pyridostigminum; Pyridostigmine Bromine; Mestinon (TN); Mestinon-SR; Regonol (TN); AQ-776/42801589; Pyridinium, 3-hydroxy-1-methyl-, dimethylcarbamate (ester); Pyridinium, 3-(((dimethylamino)carbonyl)oxy)-1-methyl-(9CI); (1-methylpyridin-1-ium-3-yl) N,N-dimethylcarbamate; 1-methyl-3-pyridiniumyl dimethylcarbamate; 3-(((Dimethylamino)carbonyl)oxy)-1-methylpyridinium
Indication
Disease Entry ICD 11 Status REF
Myasthenia gravis 8C6Y Approved [1]
Coronavirus Disease 2019 (COVID-19) 1D6Y Phase 2/3 [2]
Therapeutic Class
Parasympathomimetics
Cross-matching ID
PubChem CID
4991
ChEBI ID
CHEBI:8665
CAS Number
CAS 155-97-5
TTD Drug ID
DM8HO1L
ACDINA Drug ID
D00571

Molecule(s) Related to This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Acetylcholinesterase (AChE) TT1RS9F ACES_HUMAN Inhibitor [3]

The Expression Level of Molecule(s) in Normal Tissue of Major ADME-Related Organs

Molecule Molecule Type Gene Name Liver Colon Kidney Small Intestine
Acetylcholinesterase (AChE) DTT ACHE 1.678 1.926 1.766 5.252
Molecule Expression Atlas in Normal Tissue of Major ADME-related organs

The Expression Level of Molecule(s) between Disease Section and Healthy Individual Tissue

The Studied Disease Myasthenia gravis
ICD Disease Classification 8C6Y
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Acetylcholinesterase (AChE) DTT ACHE 6.39E-02 -1.07 -1.15
Molecular Expression Atlas between Disease Section and Healthy Individual Tissue

References

1 FDA Approved Drug Products from FDA Official Website. 2009. Application Number: (ANDA) 040457.
2 ClinicalTrials.gov (NCT04343963) Pyridostigmine in Severe SARS-CoV-2 Infection. U.S. National Institutes of Health.
3 Neuromuscular blockade, reversal agent use, and operating room time: retrospective analysis of US inpatient surgeries. Curr Med Res Opin. 2009 Apr;25(4):943-50.